Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Mai 2026 10:00 ET | Quelle: Precede Biosciences, Inc.

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLCPlasma MET test showed high concordance with tissue...
29. Mai 2026 08:00 ET | Quelle: Omniscient Neurotechnology

Omniscient Secures USD 27.2M Series D to Accelerate Commercialization of AI-Enabled Brain Technology

Omniscient (o8t®) secures $27.2M Series D funding to scale its AI-powered Quicktome® brain mapping platform and accelerate personalized brain care globally
28. Mai 2026 07:54 ET | Quelle: Research and Markets

Tumor Exosome Profiling Global Market Analysis Report 2026: $2.49 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, May 28, 2026 (GLOBE NEWSWIRE) -- The "Tumor Exosome Profiling Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor exosome profiling market has...
26. Mai 2026 08:30 ET | Quelle: Silexion Therapeutics Corp

Silexion Therapeutics Announces 1-for-10 Reverse Share Split

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
21. Mai 2026 07:07 ET | Quelle: Research and Markets

Emerging Drugs Global Market Research Report 2026: Innovations Center on Biologics, ADCs, Cell and Gene Therapies, and RNA-based Medicines, Addressing Unmet Medical Needs in Oncology, Rare Diseases

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Emerging Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.The report provides an overview of the global emerging drugs...
21. Mai 2026 04:03 ET | Quelle: Research and Markets

Next Generation RNA Therapeutics Market Research, Leading Players and Forecast Report 2026-2029 $ 2035: Advancements in This Field Continue to Overcome Challenges Related to Stability and Distribution

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Next Generation RNA Therapeutics Market (2nd Edition) by Type of Modality, Type of Molecule, Target Indication, Route of Administration, Geographical...
18. Mai 2026 08:30 ET | Quelle: Silexion Therapeutics Corp

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany...
15. Mai 2026 08:27 ET | Quelle: Silexion Therapeutics Corp

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
14. Mai 2026 09:27 ET | Quelle: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Grand Cayman, Cayman Islands, May 14, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
14. Mai 2026 09:03 ET | Quelle: Sonablate

Sonablate Launches SONA FUSION Global Registry to Advance Precision Sound Medicine and Define Future Standards in Focal Therapy

Sonablate launched their SONA FUSION Registry, a first-of-its-kind global outcomes initiative designed to unify international real-world evidence for HIFU.

Nächste Seite